Venture Life (VLG) AI Stock Analysis

• Market Cap: £75.06M
• Dividend Yield: N/A
• Average Volume (3M): 139.02K
• Price to Earnings (P/E): 99.6
• Beta (1Y): 0.26
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 165
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 127,760,994
• 10 Day Avg. Volume: 191,491
• 30 Day Avg. Volume: 139,016
• PEG Ratio: 1.18
• Price to Book (P/B): 0.66
• Price to Sales (P/S): 1.87
• P/FCF Ratio: 5.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 65 Neutral
• Price Target: 66.00p ▲(6.88% Upside)

Venture Life's stock score is primarily supported by strong technical indicators and positive corporate events, such as share buybacks and insider buying, which suggest confidence in future prospects. However, the high P/E ratio and profitability challenges weigh down the score, indicating potential overvaluation and financial risks.

Positive Factors

Cash Generation

Improved free cash flow indicates strong cash generation, providing financial flexibility for investments and debt management.

Balance Sheet Strength

A stable equity base and manageable debt levels enhance financial resilience, supporting long-term operational stability.

Operating Cash Flow

Robust operating cash flow suggests efficient cash operations, ensuring liquidity and supporting ongoing business activities.

Negative Factors

Declining Revenue

Declining revenues can impact market position and long-term growth prospects, necessitating strategic adjustments to reverse the trend.

Profitability Issues

Negative profitability margins highlight operational challenges, potentially affecting investment capacity and shareholder returns.

Margin Pressure

Decreasing margins indicate rising costs or pricing pressures, which could erode competitive advantage and financial performance.

Venture Life Business Overview & Revenue Model

Company Description

Venture Life Group plc develops and commercializes oral care products, food supplements, medical devices, dermo-cosmetics, and topical products for the ageing population in the United Kingdom, the Netherlands, China, Germany, Italy, Switzerland, rest of Europe, and internationally. It operates through Venture Life Brands and Customer Brands segments. The company offers neurology products, including NeuroAge, NeuroAge Sleep, and NeuroAge NRG food supplements to enhance alertness, cognitive function, and mental performance in healthy brain; and Original Bioscalin to treat and prevent hair loss, hair thinning, and baldness. It also provides Fungal Nail Solution, which helps to treat and prevent fungal infections; and Fungal Nail Cleanser for the hygiene of hands and feet prone to fungal nail infections under the Myco Clear brand name. In addition, the company offers UltraDEX product for bad breath; Dently Dual Action, a mouthwash, which lifts and removes plaque and bacteria from the teeth and gums; and Procto-eze plus for anal irritation, including haemorrhoids condition. Further, it provides women healthcare products comprising vonalei bacterial vaginosis, a refreshing gel; vonalei Vaginal Atrophy, a vaginal cream; vonalei candidiasis, a soothing cream-gel for thrush; and vonalei intimate cleansing foam. Additionally, it offers Cleansing Foam, Cleansing Cream, and Serum under the Rosa calma brand name; and skincare ranges to hydrate, nourish, and recondition the skin, as well as to prevent the lines and wrinkles under the Lubatti Classic and the Lubatti Anti-age brand names. The company sells its products through a network of international partners, retail pharmacies, as well as grocery multiple retailers. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.

How the Company Makes Money

Venture Life generates revenue primarily through the sale of its consumer healthcare products, which are distributed through various channels, including pharmacies, supermarkets, and online platforms. The company benefits from a diversified revenue model that includes both direct sales and partnerships with third-party distributors. Key revenue streams include product sales from its branded and private label offerings, as well as licensing agreements that allow other companies to market its products under their own brands. Additionally, Venture Life has established significant partnerships with retailers and healthcare providers, enhancing its market reach and contributing to its earnings through increased product visibility and accessibility.

Venture Life Financial Statement Overview

Summary

Venture Life faces challenges in maintaining revenue and profitability, as seen in the income statement. However, balance sheet strength and improving cash flows provide some financial resilience. The company needs to address declining revenues and margins to improve its financial health.

Income Statement

The company shows a declining revenue trend with a significant drop from 2023 to 2024. Gross Profit and Net Income margins are under pressure, turning negative in 2024, indicating profitability issues. The EBIT and EBITDA margins remain positive but have decreased, reflecting operational challenges.

Balance Sheet

The balance sheet reflects a stable equity base with a manageable debt-to-equity ratio. However, a slight increase in liabilities over time may pose a risk to financial stability. The equity ratio remains healthy, suggesting a strong asset base relative to liabilities.

Cash Flow

The cash flow statement shows improvement in free cash flow in recent years, indicating better cash generation despite declining net income. Operating cash flow remains robust relative to net income, suggesting efficient cash operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.53M	26.59M	51.41M	43.98M	32.76M	30.08M
Gross Profit	9.88M	12.19M	20.15M	17.66M	12.96M	12.85M
EBITDA	11.40M	4.32M	9.95M	7.61M	5.16M	5.60M
Net Income	-88.00K	-314.00K	921.00K	520.00K	2.40M	2.37M
Balance Sheet
Total Assets	124.91M	124.49M	119.50M	125.29M	103.63M	92.68M
Cash, Cash Equivalents and Short-Term Investments	2.01M	3.05M	5.62M	5.63M	5.24M	42.09M
Total Debt	23.28M	23.86M	24.39M	26.85M	12.73M	11.18M
Total Liabilities	49.68M	49.08M	43.24M	49.63M	30.47M	20.57M
Stockholders Equity	75.23M	75.41M	76.25M	75.66M	73.16M	72.11M
Cash Flow
Free Cash Flow	1.41M	8.34M	5.81M	1.36M	-2.66M	637.00K
Operating Cash Flow	1.44M	8.35M	8.22M	5.57M	601.00K	2.71M
Investing Cash Flow	-875.00K	-11.29M	-5.34M	-11.69M	-39.18M	-7.53M
Financing Cash Flow	-337.00K	1.78M	-2.81M	6.92M	1.50M	36.27M

Venture Life Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 61.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VLG, the sentiment is Positive. The current price of 61.75 is above the 20-day moving average (MA) of 60.11, above the 50-day MA of 56.99, and above the 200-day MA of 52.73, indicating a bullish trend. The MACD of 1.37 indicates Negative momentum. The RSI at 65.50 is Neutral, neither overbought nor oversold. The STOCH value of 91.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:VLG.

Venture Life Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	76 Outperform	£74.54M	24.55	3.62%	―	1.44%	359.79%
ANCR	67 Neutral	£171.92M	-7.02	2.83%	2.19%	8.74%	-166.50%
VLG	65 Neutral	£75.06M	99.58	―	―	―	―
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
AGY	56 Neutral	£552.73M	―	―	―	4.50%	74.32%

Venture Life Corporate Events

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback program, purchasing 75,000 ordinary shares at a volume-weighted average price of 60.50 pence per share. The acquired shares will be held as treasury shares, adjusting the total number of voting rights in the company to 127,600,994. This move is part of the company’s strategy to manage its capital structure and could potentially impact shareholder value and market perception.

Venture Life Announces Total Voting Rights Update

Venture Life Group PLC announced its total voting rights as of 30 November 2025, with 127,675,994 ordinary shares carrying voting rights out of a total issued share capital of 128,052,312 shares. This information is crucial for shareholders to determine their interest in the company’s share capital under the FCA’s Disclosure and Transparency Rules.

Venture Life Executes Share Buyback Program

Venture Life Group PLC, a leader in proactive healthy longevity within the global consumer healthcare sector, has executed a share buyback program, purchasing 75,000 ordinary shares at a volume-weighted average price of 60.57 pence per share. This move, facilitated by Cavendish Capital Markets Limited, results in a total of 128,052,312 ordinary shares in issue, with 376,318 held in treasury, impacting the total number of voting rights and potentially influencing shareholder interest notifications under FCA’s rules.

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback, purchasing 10,000 ordinary shares at a volume-weighted average price of 60.56 pence per share. This action is part of their ongoing share buyback program, and the acquired shares will be held as treasury shares. Following this transaction, the company has 128,052,312 ordinary shares in issue, with 301,318 held in treasury, impacting the total voting rights available to shareholders. This move reflects the company’s strategic financial management and may influence shareholder calculations under the FCA’s Disclosure Guidance and Transparency Rules.

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback program, purchasing 65,479 ordinary shares at a volume-weighted average price of 58.21 pence per share. These shares will be held as treasury shares, impacting the company’s total voting rights, which now stand at 127,760,994. This strategic move is part of the company’s ongoing efforts to manage its capital structure and may influence shareholder calculations under the FCA’s Disclosure Guidance and Transparency Rules.

Venture Life Group Executes Share Buyback to Optimize Capital Structure

Venture Life Group PLC has executed a share buyback, purchasing 20,000 ordinary shares at a price of 59.21 pence each, as part of its ongoing share buyback programme. The acquired shares will be held as treasury shares, adjusting the total number of voting rights in the company to 127,826,473. This move is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Venture Life Group Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback, purchasing 120,000 ordinary shares at a volume-weighted average price of 57.81 pence per share, as part of its share buyback program. This transaction, conducted through Cavendish Capital Markets Limited, results in the company holding these shares as treasury shares, impacting the total number of voting rights available. The move is likely aimed at optimizing the company’s capital structure and potentially increasing shareholder value.

Venture Life Executes Share Buyback Program

Venture Life Group PLC has executed a share buyback program, purchasing 61,599 ordinary shares at an average price of 58.9025 pence per share. These shares will be held as treasury shares, affecting the total number of voting rights in the company, which now stands at 127,966,473. This move is part of the company’s strategic financial management, potentially impacting shareholder value and market perception.

Venture Life Executes Share Buyback to Strengthen Capital Structure

Venture Life Group PLC, a leader in the global consumer healthcare sector, has executed a share buyback program, acquiring 24,240 ordinary shares at an average price of 59.65 pence each. These shares will be held as treasury shares, affecting the total voting rights in the company, which now stands at 128,028,072. This move is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

Venture Life Director Increases Stake in Company

Venture Life Group PLC announced that Mark Adams, a Non-Executive Director, has purchased 88,999 ordinary shares of the company, increasing his total holdings to 308,897 shares, which represents approximately 0.24% of the company’s issued share capital. This transaction underscores the confidence of the company’s leadership in its market position and future prospects, potentially influencing stakeholder perceptions and market dynamics.

Venture Life Group Initiates Share Buyback Programme to Boost Shareholder Value

Venture Life Group PLC has announced a share buyback programme following the release of its interim results for the first half of 2025. The company believes its shares are undervalued and aims to enhance earnings per share and shareholder value through this programme, which will be funded by existing cash resources. The buyback will involve repurchasing up to 10% of the company’s issued share capital by July 2026, managed by Cavendish Capital Markets Limited. This move is expected to strengthen Venture Life’s market position and potentially increase its stock value, although the programme’s completion is not guaranteed and may be adjusted based on market conditions.

Venture Life Group Reports Strong Revenue Growth and Strategic Divestments

Venture Life Group PLC announced robust financial results for the first half of 2025, with a 43.1% increase in group revenue and a significant improvement in gross profit. The company has strategically divested its contract development and manufacturing operations and certain non-core products, raising €62 million in cash, which positions it as a higher margin, brand-focused consumer healthcare business. With a net cash position of £34.1 million, Venture Life plans to invest in organic and acquired growth, launch a share buyback program, and pursue potential mergers and acquisitions, enhancing its market positioning and operational efficiency.

Venture Life Group Announces Live Interim Results Presentation

Venture Life Group PLC announced that CEO Jerry Randall and CFO Daniel Wells will present the company’s Interim Results for the period ended 30 June 2025 via a live presentation on Investor Meet Company. This event, scheduled for 01 October 2025, is open to all existing and potential shareholders, allowing them to submit questions and engage with the company’s leadership. This initiative reflects Venture Life’s commitment to transparency and stakeholder engagement, potentially enhancing investor relations and market confidence.

Venture Life Group Adjusts Accounting Reference Date to Enhance Strategic Alignment

Venture Life Group PLC, a leader in the global consumer healthcare sector, has announced a change in its accounting reference date from 31 December to 31 May to better align with its revised strategy. This change aims to reduce revenue seasonality and manage specific operating costs more effectively, impacting the company’s financial calendar with new dates for publishing unaudited interim and audited accounts.